EQS Group-Ad-hoc: Lonza Group AG / Key word(s): Agreement/Expansion 
Lonza and Moderna Announce Further Collaboration For Drug Substance Manufacturing of COVID-19 Vaccine Moderna in the 
Netherlands 
02-Jun-2021 / 07:00 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 KR 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
  . A new drug substance production line at Lonza's site in Geleen, Netherlands will complement the existing production 
    network and support the manufacture of up to an additional 300 million doses per year 
  . Operations are expected to begin by the end of 2021 
Quote from Jean-Christophe Hyvert, President, Biologics and Cell & Gene, Lonza: 
'Once more, we are pleased to leverage our network as we expand our collaboration with Moderna further to extend our 
mRNA manufacturing to Lonza Geleen (NL). The extension reflects the continuing growth of our strategic collaboration 
with Moderna. We are proud to play our part in controlling the COVID-19 pandemic and look forward to bringing to bear 
our experience from Portsmouth (US) and Visp (CH) at our Geleen site in the Netherlands.' 
Basel, Switzerland, 2 June 2021 - Lonza today announced the expansion of its collaboration with Moderna, a 
biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The expanded collaboration will 
further extend the manufacture of the drug substance for the COVID-19 Vaccine Moderna and provides for the installation 
of a new manufacturing line for drug substance production at Lonza's Geleen (NL) site. 
The new production line in Geleen (NL) will complement Lonza's existing drug substance production network for COVID-19 
Vaccine Moderna and deliver a crucial manufacturing step to increase overall drug substance output. As such, the new 
production line will contribute to the supply of up to an additional 300 million doses per year, at a 50ug dose, once 
operating at full capacity. 
In May 2020, Lonza and Moderna announced a ten-year strategic collaboration agreement to enable the manufacture of 
Moderna's COVID-19 vaccine and additional Moderna products in the future. Since then, Lonza has installed three 
production lines at its Visp (CH) site and one production line in Portsmouth (US). In April 2021, Lonza and Moderna 
entered a new agreement to add three further production lines at its Visp (CH) site. 
The new production line in Geleen (NL) is expected to be operational by the end of 2021. Lonza will leverage its 
existing infrastructure in Geleen (NL) to provide fast build-out and ramp-up of operations. 
About Lonza 
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness 
and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide 
range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific 
expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the 
healthcare sector. 
Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 14,000 full-time 
employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own 
business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 
with a CORE EBITDA of CHF 1.4 billion. Find out more at www.lonza.com 
Follow @Lonza on LinkedIn 
Follow @LonzaGroup on Twitter 
Lonza Contact Details 
Victoria Morgan 
Head of External Communications 
Lonza Group Ltd 
Tel +41 61 316 2283 
victoria.morgan@lonza.com 
Dirk Oehlers 
Investor Relations 
Lonza Group Ltd 
Tel +41 61 316 8540 
dirk.oehlers@lonza.com 
=---------------------------------------------------------------------------------------------------------------------- 
End of ad hoc announcement 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Lonza Group AG 
              Münchensteinerstrasse 38 
              4052 Basel 
              Switzerland 
Phone:        +4161 316 81 11 
Internet:     www.lonza.com 
ISIN:         CH0013841017 
Valor:        1384101 
Listed:       SIX Swiss Exchange 
EQS News ID:  1203374 
 
End of Announcement EQS Group News Service 
=------------

1203374 02-Jun-2021 CET/CEST


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1203374&application_name=news

(END) Dow Jones Newswires

June 02, 2021 01:01 ET (05:01 GMT)